The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

Ritonavir, originally developed as HIV protease inhibitor, is widely used as a booster in several HIV pharmacotherapy regimens and more recently in Covid-19 treatment (e.g., Paxlovid). Its boosting capacity is due to the highly potent irreversible inhibition of the cytochrome P450 (CYP) 3 A enzyme,...

Descripción completa

Detalles Bibliográficos
Autores principales: Loos, Nancy H.C., Beijnen, Jos H., Schinkel, Alfred H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065864/
https://www.ncbi.nlm.nih.gov/pubmed/37004323
http://dx.doi.org/10.1016/j.biopha.2023.114636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065864/
https://www.ncbi.nlm.nih.gov/pubmed/37004323
http://dx.doi.org/10.1016/j.biopha.2023.114636

Ejemplares similares